Table 1 Baseline characteristics
Variables | Rivaroxaban (n = 25) | Warfarin (n = 26) |
|---|---|---|
Age, year | 72.3 ± 7.6 | 70.7 ± 9.0 |
Females | 2 (8.0) | 2 (7.7) |
Body mass index, kg/m2 | 25.1 ± 4.4 | 24.5 ± 3.4 |
Systolic blood pressure, mm Hg | 127.1 ± 16.1 | 132.9 ± 19.4 |
Diastolic blood pressure, mm Hg | 77.4 ± 14.2 | 80.9 ± 12.8 |
Heart rare, beats/min | 77.7 ± 12.3 | 84.6 ± 14.4 |
eGFR, mL/min/1.73 m2 | 57.3 ± 11.4 | 59.3 ± 11.7 |
58.2 [48.7, 66.0] | 60.6 [52.6, 63.8] | |
Currently smoking | 3 (12.0) | 3 (11.5) |
Previous history | ||
Hypertension | 20 (80.0) | 23 (88.5) |
Diabetes mellitus | 4 (16.0) | 4 (15.4) |
ASCVDs | 8 (32.0) | 8 (30.8) |
Heart failure | 10 (40.0) | 12 (46.2) |
Type of AF | ||
Paroxysmal | 4 (16.0) | 5 (19.2) |
Persistent | 8 (32.0) | 7 (26.9) |
Permanent | 13 (52.0) | 14 (53.8) |
CHADS2 score | 2 [1, 3] | 2 [1, 3] |
CHADS2-VASc score | 3 [2, 4] | 3 [2, 4] |
Medications | ||
Pre-warfarin | 20 (80.0) | 21 (80.8) |
ACE inhibitor or ARB | 13 (52.0) | 15 (57.7) |
Beta-blocker | 9 (36.0) | 7 (26.9) |
Calcium channel blocker | 14 (56.0) | 16 (61.5) |
Diuretic | 6 (24.0) | 7 (26.9) |
Statin | 10 (40.0) | 4 (15.4) |
Antiplatelet | 5 (20.0) | 0 (0.0) |
